Generic Name and Formulations:
Clonidine 0.1mg/day, 0.2mg/day, 0.3mg/day; each transdermal patch delivers dose for 1 week.
Boehringer Ingelheim Pharmaceuticals
Indications for CATAPRES-TTS:
Apply to intact, hairless area of upper arm or anterior torso; rotate application sites. Taper withdrawal of other antihypertensives. Initially one 0.1mg/day patch weekly; may increase after 1–2 weeks; max 0.6mg/day.
Sinus node dysfunction. AV block. Pheochromocytoma: not effective. Conduction disturbances. Renal dysfunction. Avoid abrupt cessation. If local reaction occurs from patch, using tabs may cause generalized rash. Discontinue 4hrs before surgery; resume as soon as possible after surgery. Patch: remove before defibrillation, cardioversion, or MRI. Pregnancy (Cat.C). Nursing mothers.
Central alpha agonist.
Antagonized by tricyclic antidepressants. Potentiates CNS depressants. Orthostatic regulation disturbances (eg, orthostatic hypotension, dizziness, fatigue) possible with neuroleptics. Monitor heart rate in patients receiving agents known to affect sinus node function or AV nodal conduction (eg, digitalis, calcium channel blockers, β-blockers).
Dry mouth, dry eye, drowsiness, dizziness, weakness, constipation, sedation, rash, myalgia, urticaria, nausea, insomnia, agitation, orthostatic hypotension, impotence, arrhythmias.
Endocrinology Advisor Articles
- Two Phases of C-Peptide Decline Identified in Type I Diabetes
- Dulaglutide Effective for Patients With T2D, Moderate to Severe CKD
- Incidence of Diabetes Influenced by Endocrine-Disrupting Chemicals in the Environment
- Guidelines for Management of Hypothalamic-Pituitary, Growth Disorders in Childhood Cancer Survivors
- Romosozumab: Effective in Men With Osteoporosis
- Using Latent Class Trajectory Analysis to Determine Glucose Response Curve Patterns
- First CGM System With Implantable Glucose Sensor Approved
- Adjunctive Metformin for Insulin Resistance in T1D: A Clinical Perspective
- Risk for Below Knee Amputations With Canagliflozin vs Other Antihyperglycemic Agents
- Empagliflozin, Linagliptin Combination Therapy vs Linagliptin Monotherapy for Type 2 Diabetes
- NT-proBNP May Predict Cardiovascular Outcomes in Type 2 Diabetes
- Placebo Effect of Various Female Sexual Dysfunction Drug Txs Assessed
- Link Between Oral Diabetes Medications and Bullous Pemphigoid
- Calcium Channel Blocker May Benefit Patients With Type 1 Diabetes
- β-Cell Function in Youth With Impaired Glucose Tolerance, T2D